According to our (Global Info Research) latest study, the global Biciruizumab market size was valued at US$ 2592 million in 2025 and is forecast to a readjusted size of US$ 8879 million by 2032 with a CAGR of 14.6% during review period.
Bevacizumab is a recombinant humanized monoclonal antibody primarily used for the treatment of various types of cancer, including colorectal cancer, non-small cell lung cancer, and renal cell carcinoma. It works by targeting and inhibiting the action of vascular endothelial growth factor (VEGF), preventing the formation of new blood vessels in tumors, thus reducing tumor blood supply and inhibiting tumor growth and spread. Bevacizumab is widely used in combination cancer therapies, typically in conjunction with chemotherapy or other targeted drugs to enhance therapeutic efficacy. The drug is administered intravenously and has been approved for clinical use in multiple countries and regions.In 2025, global Bimekizumab production reached approximately 1.2 million vials.
Bevacizumab holds an important position in the global cancer drug market, especially in the treatment of various solid tumors, such as colorectal cancer, non-small cell lung cancer, and renal cell carcinoma. With the continuous rise in cancer prevalence and ongoing innovations in cancer treatment, the market demand for Bevacizumab is steadily increasing. This drug works by inhibiting vascular endothelial growth factor (VEGF), blocking tumor angiogenesis, and significantly improving treatment outcomes, particularly when used in combination with chemotherapy and other targeted therapies. The market prospects for Bevacizumab are very promising, particularly in developing countries and emerging markets, where improvements in healthcare infrastructure and the widespread adoption of cancer screening will benefit more patients. Although Bevacizumab is priced relatively high and faces competition from generic drugs, it remains a core component of many cancer treatment regimens. Additionally, as research into Bevacizumab’s use in other cancer types continues to expand, it is expected that the drug’s indications will continue to grow, further driving market growth.
This report is a detailed and comprehensive analysis for global Biciruizumab market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Biciruizumab market size and forecasts, in consumption value ($ Million), sales quantity (Units), and average selling prices (US$/Unit), 2021-2032
Global Biciruizumab market size and forecasts by region and country, in consumption value ($ Million), sales quantity (Units), and average selling prices (US$/Unit), 2021-2032
Global Biciruizumab market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (Units), and average selling prices (US$/Unit), 2021-2032
Global Biciruizumab market shares of main players, shipments in revenue ($ Million), sales quantity (Units), and ASP (US$/Unit), 2021-2026
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Biciruizumab
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Biciruizumab market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Roche, Chugai Pharmaceutical, Amgen, Pfizer, Qilu Pharmaceutical, Innovent Biologics, Jiangsu Hengrui Medicine, Shandong Boan Biotechnology, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market Segmentation
Biciruizumab market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
100 mg/4 mL
320 mg/2 mL
Market segment by Specification
Bimekizumab In Combination With Methotrexate
Bimekizumab Combined With Topical Corticosteroids
Market segment by Sales Channels
Hospital
Retail
Online
Market segment by Dosage Form
Intravenous Injection
Subcutaneous Injection
Market segment by Application
Psoriasis
Ankylosing Spondylitis
Hidradenitis Suppurativa
Others
Major players covered
Roche
Chugai Pharmaceutical
Amgen
Pfizer
Qilu Pharmaceutical
Innovent Biologics
Jiangsu Hengrui Medicine
Shandong Boan Biotechnology
Market segment by region, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Biciruizumab product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Biciruizumab, with price, sales quantity, revenue, and global market share of Biciruizumab from 2021 to 2026.
Chapter 3, the Biciruizumab competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Biciruizumab breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2021 to 2032.
Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2021 to 2032.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2021 to 2026.and Biciruizumab market forecast, by regions, by Type, and by Application, with sales and revenue, from 2027 to 2032.
Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
Chapter 13, the key raw materials and key suppliers, and industry chain of Biciruizumab.
Chapter 14 and 15, to describe Biciruizumab sales channel, distributors, customers, research findings and conclusion.
Summary:
Get latest Market Research Reports on Biciruizumab. Industry analysis & Market Report on Biciruizumab is a syndicated market report, published as Global Biciruizumab Market 2026 by Manufacturers, Regions, Type and Application, Forecast to 2032. It is complete Research Study and Industry Analysis of Biciruizumab market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.